According to these observations, several agents, such as all-trans retinoic acid (ATRA), immunomodulatory drugs (IMiDs), HDACis and DNMTis, may increase the expression of CD38 in myeloma cells and subsequently improve anti-CD38 treatments [11,18,19,38]. This evidence concerns the gene CD38 and plasma cell myeloma.